[1] Web. https://www.who.int/news-room/fact-sheets/detail/cancer.
[2] Staff, N. P., Grisold, A., Grisold, W., & Windebank, A. J. (2017). Chemotherapy-induced peripheral neuropathy: A current review. Annals of neurology, 81(6), 772–781.
[3] Chen, H. H. W., & Kuo, M. T. (2017). Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget, 8(37), 62742–62758.
[4] Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022). Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. Journal of hematology & oncology, 15(1), 143.
[5] Kannaiyan, R., & Mahadevan, D. (2018). A comprehensive review of protein kinase inhibitors for cancer therapy. Expert review of anticancer therapy, 18(12), 1249–1270.
[6] Arora, A., & Scholar, E. M. (2005). Role of tyrosine kinase inhibitors in cancer therapy. The Journal of pharmacology and experimental therapeutics, 315(3), 971–979.
[7] Peerzada, M. N., Dar, M. S., & Verma, S. (2023). Development of tubulin polymerization inhibitors as anticancer agents. Expert opinion on therapeutic patents, 33(11), 797–820.
[8] Hawash M. (2022). Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy. Biomolecules, 12(12), 1843.
[9] Yakkala, P. A., Penumallu, N. R., Shafi, S., & Kamal, A. (2023). Prospects of Topoisomerase Inhibitors as Promising Anti-Cancer Agents. Pharmaceuticals (Basel, Switzerland), 16(10), 1456.
[10] Nitiss J. L. (2009). Targeting DNA topoisomerase II in cancer chemotherapy. Nature reviews. Cancer, 9(5), 338–350.
[11] Pérez-Salvia, M., & Esteller, M. (2017). Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics, 12(5), 323–339.
[12] To, K. K. W., Xing, E., Larue, R. C., & Li, P. K. (2023). BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. Molecules (Basel, Switzerland), 28(7), 3043.
[13] Wang, Z. Q., Zhang, Z. C., Wu, Y. Y., Pi, Y. N., Lou, S. H., Liu, T. B., Lou, G., & Yang, C. (2023). Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy. Signal transduction and targeted therapy, 8(1), 420.
[14] Giammona, A., Crivaro, E., & Stecca, B. (2023). Emerging Roles of Hedgehog Signaling in Cancer Immunity. International journal of molecular sciences, 24(2), 1321.
[15] Cortes, J. E., Gutzmer, R., Kieran, M. W., & Solomon, J. A. (2019). Hedgehog signaling inhibitors in solid and hematological cancers. Cancer treatment reviews, 76, 41–50.
[16] Neckers, L. (2007). Heat shock protein 90: the cancer chaperone. Heat Shock Proteins in Cancer: 231-252.
[17] Zhang, J., Li, H., Liu, Y., Zhao, K., Wei, S., Sugarman, E. T., Liu, L., & Zhang, G. (2022). Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance. Cells, 11(18), 2778.
[18] Liang, J., Tian, C., Liu, L., Zeng, X., & Zhang, Y. (2024). Targeting CENP-E augments immunotherapy in non-small cell lung cancer via stabilizing PD-L1. International immunopharmacology, 126, 111294.
[19] El-Arabey, A. A., Salama, S. A., & Abd-Allah, A. R. (2018). CENP-E as a target for cancer therapy: Where are we now?. Life sciences, 208, 192–200.
[20] Tang, H., Wang, L., Wang, T., Yang, J., Zheng, S., Tong, J., Jiang, S., Zhang, X., & Zhang, K. (2023). Recent advances of targeting nicotinamide phosphoribosyltransferase (NAMPT) for cancer drug discovery. European journal of medicinal chemistry, 258, 115607.
[21] Gasparrini, M., & Audrito, V. (2022). NAMPT: A critical driver and therapeutic target for cancer. The international journal of biochemistry & cell biology, 145, 106189.
[22] Ammer, L. M., Vollmann-Zwerenz, A., Ruf, V., Wetzel, C. H., Riemenschneider, M. J., Albert, N. L., Beckhove, P., & Hau, P. (2020). The Role of Translocator Protein TSPO in Hallmarks of Glioblastoma. Cancers, 12(10), 2973.
[23] Bhoola, N. H., Mbita, Z., Hull, R., & Dlamini, Z. (2018). Translocator Protein (TSPO) as a Potential Biomarker in Human Cancers. International journal of molecular sciences, 19(8), 2176.
[24] Khwaza, V., Mlala, S., Oyedeji, O. O., & Aderibigbe, B. A. (2021). Pentacyclic Triterpenoids with Nitrogen-Containing Heterocyclic Moiety, Privileged Hybrids in Anticancer Drug Discovery. Molecules (Basel, Switzerland), 26(9), 2401.
[25] Ali, I., Lone, M. N., Al-Othman, Z. A., Al-Warthan, A., & Sanagi, M. M. (2015). Heterocyclic Scaffolds: Centrality in Anticancer Drug Development. Current drug targets, 16(7), 711–734.
[26] Ayana, R., Vijayakumar, B., Athulya, P., Anjana, V. S., Vismaya, K. V., & Swarnalatha, G. (2021). A short review on heterocyclic compounds showing Anti-Breast cancer activity. Journal of Scientific Research, 13(3), 1075–1098.
[27] Viegas-Junior, C., Danuello, A., da Silva Bolzani, V., Barreiro, E. J., & Fraga, C. A. (2007). Molecular hybridization: a useful tool in the design of new drug prototypes. Current medicinal chemistry, 14(17), 1829–1852.
[28] Ganesh, B. H., Raj, A. G., Aruchamy, B., Nanjan, P., Drago, C., & Ramani, P. (2024). Pyrrole: A Decisive Scaffold for the Development of Therapeutic Agents and Structure-Activity Relationship. ChemMedChem, 19(1), e202300447.
[29] Pegklidou, K., Papastavrou, N., Gkizis, P., Komiotis, D., Balzarini, J., & Nicolaou, I. (2015). N-substituted pyrrole-based scaffolds as potential anticancer and antiviral lead structures. Medicinal chemistry (Shariqah (United Arab Emirates)), 11(6), 602–608.
[30] Mateev, E., Georgieva, M., & Zlatkov, A. (2022). Pyrrole as an Important Scaffold of Anticancer Drugs: Recent Advances. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for
Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 25, 24–40.
[31] Sahu, R., Shah, K., Gautam, Y., & Sahu, K. (2023). Pyrazine Moiety: Recent developments in cancer treatment. Current Organic Chemistry, 27(10), 821–843.
[32] Chen, G. Q., Guo, H. Y., Quan, Z. S., Shen, Q. K., Li, X., & Luan, T. (2023). Natural Products-Pyrazine Hybrids: A Review of Developments in Medicinal Chemistry. Molecules (Basel, Switzerland), 28(21), 7440.
[33] Jaballah, M. Y., Serya, R. T., & Abouzid, K. (2017). Pyridazine Based Scaffolds as Privileged Structures in anti-Cancer Therapy. Drug research, 67(3), 138–148.
[34] He, Z. X., Gong, Y. P., Zhang, X., Ma, L. Y., & Zhao, W. (2021). Pyridazine as a privileged structure: An updated review on anticancer activity of pyridazine containing bioactive molecules. European journal of medicinal chemistry, 209, 112946.
[35] Lish, A. B., Foroumadi, A., Kolvari, E., & Safari, F. (2023). Synthesis and Biological Evaluation of 12-Aryl-11-hydroxy-5,6-dihydropyrrolo[2″,1″:3′,4′]pyrazino[1′,2′:1,5]pyrrolo[2,3-d]pyridazine-8(9H)-one Derivatives as Potential Cytotoxic Agents. ACS Omega, 8(45), 42212–42224.[36] Liu, H., Li, Z., Huo, S., Wei, Q., & Ge, L. (2020). Induction of G0/G1 phase arrest and apoptosis by CRISPR/Cas9-mediated knockout of CDK2 in A375 melanocytes. Molecular and clinical oncology, 12(1), 9–14.
[37] Ayati, A., Oghabi Bakhshaiesh, T., Moghimi, S., Esmaeili, R., Majidzadeh-A, K., Safavi, M., Firoozpour, L., Emami, S., & Foroumadi, A. (2018). Synthesis and biological evaluation of new coumarins bearing 2,4-diaminothiazole-5-carbonyl moiety. European journal of medicinal chemistry, 155, 483–491.
